Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETON Eton Pharmaceuticals	$11.83 -5.4%	$15.26	$3.03 ▼ $18.41	$317.26M	1.34	165,798 shs	512,099 shs
MREO Mereo BioPharma Group	$1.99 -10.0%	$2.65	$1.93 ▼ $5.02	$308.74M	0.71	1.02 million shs	1.69 million shs
OCX OncoCyte	$2.77 -5.1%	$2.88	$1.92 ▼ $4.75	$79.22M	0.79	66,304 shs	65,248 shs
RNAC Cartesian Therapeutics	$10.00 -19.0%	$17.32	$9.12 ▼ $41.87	$259.07M	0.55	117,311 shs	340,911 shs

Unlock the Potential in Options Trading

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETON Eton Pharmaceuticals	-5.36%	-9.14%	-22.02%	-9.00%	+228.61%
MREO Mereo BioPharma Group	-9.95%	-13.48%	-21.34%	-46.65%	-41.64%
OCX OncoCyte	-5.14%	-13.71%	-23.48%	+16.88%	-5.78%
RNAC Cartesian Therapeutics	-18.96%	-31.22%	-44.20%	-40.65%	-31.99%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETON Eton Pharmaceuticals	2.7082 of 5 stars	3.5	5.0	2.4	0.8	0.6
MREO Mereo BioPharma Group	2.5192 of 5 stars	3.6	4.0	2.8	1.7	0.0
OCX OncoCyte	2.3998 of 5 stars	3.4	2.0	3.1	2.5	0.6
RNAC Cartesian Therapeutics	2.0547 of 5 stars	3.4	1.0	2.3	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETON Eton Pharmaceuticals	3.00	Buy	$27.67	133.87% Upside
MREO Mereo BioPharma Group	3.25	Buy	$7.71	287.65% Upside
OCX OncoCyte	2.75	Moderate Buy	$4.56	64.71% Upside
RNAC Cartesian Therapeutics	2.80	Moderate Buy	$42.14	321.43% Upside

Current Analyst Ratings Breakdown

Latest OCX, MREO, ETON, and RNAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/28/2025	OCX OncoCyte	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
3/27/2025	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
3/26/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/25/2025	OCX OncoCyte	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$4.00 ➝ $4.00
3/25/2025	OCX OncoCyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.25 ➝ $4.25
3/19/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $26.00
3/19/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $24.00
3/19/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
3/18/2025	MREO Mereo BioPharma Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00 ➝ $7.00
3/14/2025	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $40.00
3/13/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $41.00

(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETON Eton Pharmaceuticals	$39.01M	8.13	$0.00 per share	4,502.79	$0.60 per share	19.72
MREO Mereo BioPharma Group	$1M	308.74	N/A	N/A	$0.36 per share	5.53
OCX OncoCyte	$1.88M	42.12	N/A	N/A	$2.48 per share	1.12
RNAC Cartesian Therapeutics	$38.91M	6.66	N/A	N/A	($82.38) per share	-0.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETON Eton Pharmaceuticals	-$940K	-$0.15	N/A	23.66	N/A	-15.81%	-36.29%	-16.84%	5/8/2025 (Estimated)
MREO Mereo BioPharma Group	-$29.47M	-$0.06	N/A	N/A	N/A	N/A	N/A	N/A	5/23/2025 (Estimated)
OCX OncoCyte	-$27.78M	-$4.40	N/A	N/A	N/A	-6,122.29%	-269.32%	-59.71%	5/13/2025 (Estimated)
RNAC Cartesian Therapeutics	-$219.71M	-$52.83	N/A	N/A	N/A	-510.72%	N/A	-6.03%	5/6/2025 (Estimated)

Latest OCX, MREO, ETON, and RNAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/26/2025	Q4 2024	MREO Mereo BioPharma Group	$0.02	-$0.01	-$0.03	-$0.01	$72.50 million	N/A
3/24/2025	Q4 2024	OCX OncoCyte	-$0.40	$0.48	+$0.88	-$1.93	$0.16 million	$1.49 million
3/18/2025	Q4 2024	ETON Eton Pharmaceuticals	-$0.02	-$0.02	N/A	-$0.02	$10.53 million	$11.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
OCX OncoCyte	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETON Eton Pharmaceuticals	N/A	1.51	1.41
MREO Mereo BioPharma Group	N/A	6.10	6.10
OCX OncoCyte	N/A	0.53	0.50
RNAC Cartesian Therapeutics	N/A	10.70	10.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETON Eton Pharmaceuticals	27.86%
MREO Mereo BioPharma Group	62.83%
OCX OncoCyte	55.35%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
ETON Eton Pharmaceuticals	14.89%
MREO Mereo BioPharma Group	4.13%
OCX OncoCyte	1.58%
RNAC Cartesian Therapeutics	57.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.17 million	Optionable
MREO Mereo BioPharma Group	40	155.15 million	148.74 million	Optionable
OCX OncoCyte	120	28.60 million	17.18 million	No Data
RNAC Cartesian Therapeutics	64	25.91 million	10.70 million	Optionable

OCX, MREO, ETON, and RNAC Headlines

Recent News About These Companies

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

April 5 at 1:55 AM | americanbankingnews.com

Cartesian Therapeutics Announces New Employment Inducement Grants

April 2 at 7:05 AM | globenewswire.com

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

April 1, 2025 | globenewswire.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by Analysts

April 1, 2025 | marketbeat.com

Substantial Insider Buying: American Express, Asana, and More

March 30, 2025 | 247wallst.com

Timothy Springer Spends US$1.4m On Cartesian Therapeutics Stock

March 23, 2025 | finance.yahoo.com

Analysts Set Expectations for RNAC FY2025 Earnings

March 20, 2025 | marketbeat.com

Oppenheimer Reaffirms Their Hold Rating on Cartesian Therapeutics (RNAC)

March 17, 2025 | markets.businessinsider.com

Erste Asset Management GmbH Has $3.26 Million Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)

March 16, 2025 | marketbeat.com

Cartesian Therapeutics, Inc.: Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

March 16, 2025 | finanznachrichten.de

HC Wainwright Issues Pessimistic Forecast for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price

March 15, 2025 | marketbeat.com

Needham & Company LLC Reaffirms "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)

March 14, 2025 | marketbeat.com

Cartesian Therapeutics Advances mRNA Therapy Pipeline

March 14, 2025 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and ProQR (PRQR)

March 14, 2025 | markets.businessinsider.com

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

March 13, 2025 | finance.yahoo.com

TD Cowen Sticks to Its Buy Rating for Cartesian Therapeutics (RNAC)

March 13, 2025 | markets.businessinsider.com

Cartesian Therapeutics announces employment inducement grant

March 6, 2025 | markets.businessinsider.com

Cartesian Therapeutics Announces New Employment Inducement Grant

March 6, 2025 | globenewswire.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Rating of "Moderate Buy" by Analysts

March 6, 2025 | marketbeat.com

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

February 18, 2025 | globenewswire.com

Cartesian Therapeutics Announces New Employment Inducement Grants

February 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCX, MREO, ETON, and RNAC Company Descriptions

Eton Pharmaceuticals NASDAQ:ETON

$11.83 -0.67 (-5.36%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$11.66 -0.17 (-1.39%)

As of 04/4/2025 06:42 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Mereo BioPharma Group NASDAQ:MREO

$1.99 -0.22 (-9.95%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$1.92 -0.07 (-3.72%)

As of 04/4/2025 07:43 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

OncoCyte NASDAQ:OCX

$2.77 -0.15 (-5.14%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$2.74 -0.02 (-0.90%)

As of 04/4/2025 04:05 PM Eastern

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Cartesian Therapeutics NASDAQ:RNAC

$10.00 -2.34 (-18.96%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$9.95 -0.05 (-0.50%)

As of 04/4/2025 04:44 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time